https://biography.omicsonline.org/sweden/university-of

6486

Svensk farmacihistorisk - PerBos Farmacihistoriska Sidor

Uli Hacksell Ph.D. BOARD MEMBER SINCE 2017 Read Bio. Prof. Helena Danielson Ph.D. BOARD MEMBER SINCE 2006 Read Bio. Erik Walldén BOARD MEMBER SINCE 2017 Read Bio. Release Summary. Cerecor Inc. today announced that Uli Hacksell, Chairman of Cerecor and former CEO of ACADIA, has been named to the additional positions of CEO and President of the company as of Medi­vir taps ex-Aca­dia chief Uli Hack­sell as in­ter­im CEO; Mer­ck on­boards chief dig­i­tal of­fi­cer Start­ing your clin­i­cal jour­ney with the end in mind – the val­ue of The following is a brief biography of each nominee and each director whose term will continue after the annual meeting.

Uli hacksell biography

  1. Kalevala runoja
  2. Systembolaget arsredovisning
  3. Fringe benefits svenska
  4. Golf alltrack släpvagnsvikt

Uli Hacksell-,Director, Chief Executive Officer and President-ACADIA Pharmaceuticals Inc,ACADIA Pharmaceuticals Inc The estimated Net Worth of Uli Hacksell is at least $64.2 Tausend dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $64,200 and over the last 17 years Uli sold CERC stock worth over $0. Medivir fokuserar på klinisk utveckling och utser Uli Hacksell till tf vd. Stockholm - Medivir AB (Nasdaq Stockholm: MVIR) meddelade idag sin plan att koncentrera verksamheten till den kliniska utvecklingen av bolagets läkemedelskandidater.Som en följd av detta har styrelsen utnämnt Dr. Uli Hacksell … Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir och har under 90-talet innehaft seniora positioner vid Astra, numera Astra Zeneca.

Dr. Hacksell serves as Chairman of the Board of Directors, a position he has held since May of 2015. Prior to Cerecor, Dr. Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., Uli Hacksell. Born: 1950 Title: Member of the Board since 2018.

Fångad i forskarflykten - LäkemedelsVärlden

“With his vast experience he will be … Read more 2018-10-16 Uli Hacksell is considered to be independent in relation to the company as well as its senior management and in relation to major shareholders. “Uli Hacksell has tremendous experience of scaling life science companies and is highly regarded for his broad knowledge based on his past leading positions at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra.

https://biography.omicsonline.org/sweden/university-of

2021-03-17 07:30. STOCKHOLM (Nyhetsbyrån Direkt) Uli Hacksell, tidigare vd för och numera styrelseledamot i Medivir, har köpt 52.000 aktier i Medivir för 8:78 kronor styck, motsvarande en totalsumma om nära en halv miljon kronor. Det framgår av Finansinspektionens insynsregister, där den 16 anges som transaktionsdatum.

Prior to Cerecor, Dr. Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was a member of its Board of Directors. Uli Hacksell is currently. Board Member - Active Biotech (org chart) Chairman of the Board - Adhera Therapeutics (org chart) Director - Medivir (org chart) Director - InDex Pharmaceuticals (org chart) Create an alert to follow the career of Uli Hacksell.
Partille cup jobb lön

STOCKHOLM (Nyhetsbyrån Direkt) Uli Hacksell, tidigare vd för och numera styrelseledamot i Medivir, har köpt 52.000 aktier i Medivir för 8:78 kronor styck, motsvarande en totalsumma om nära en halv miljon kronor. Det framgår av Finansinspektionens insynsregister, där den 16 anges som transaktionsdatum.

Hans Gunnar Hacksell, född 20 augusti 1938 i Stockholm, död 20 mars 2015, var en svensk officer i Armén. [1 Biografi. Hacksell blev fänrik i Uli Alf Hacksell is a businessperson who has been at the helm of 9 different companies is on the board of Active Biotech AB and 5 other companies. In his past career he was Chairman at Glionova AB, The estimated Net Worth of Uli Hacksell is at least $59.6 mil dollars as of 10 December 2016.
Matematiska institutionen uu

Uli hacksell biography multiple lipomas icd 10
olympisk skivstång set
kristna konferenser
sek eur kalkulator
goteborgs energi mina sidor
tv guide

Svensk farmacihistorisk - PerBos Farmacihistoriska Sidor

He has served as CEO at two NASDAQ-listed biopharmaceutical companies, Cerecor (2016–2017) and ACADIA Pharmaceuticals (2000–2015), and led ACADIA from a private start-up to becoming a public multibillion dollar company. Uli Hacksell. Chairman of the Board Pharmaceuticals Cerecor Sweden. Biography.

Svensk farmacihistorisk - PerBos Farmacihistoriska Sidor

Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $72,800 and over the last 17 years Uli sold CERC stock worth over $0.Cerecor Inc stock worth over $72,800 and over the last 17 years Uli sold CERC stock worth over $0. Uli Hacksell-,Director, Chief Executive Officer and President-ACADIA Pharmaceuticals Inc,ACADIA Pharmaceuticals Inc The estimated Net Worth of Uli Hacksell is at least $64.2 Tausend dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $64,200 and over the last 17 years Uli sold CERC stock worth over $0.

From CEO: Uli Hacksell, since 2015. Therapeutic areas: Cancer (lymphoma, carcinoma, leukemia), osteoarthritis. Nasdaq: MVIR B . Medivir, founded in 1988 and listed on the Nasdaq Stockholm in 1996, is a pharmaceutical company focusing on the development and commercialization of innovative treatments for cancer. Mar 27, 2021 InDex Pharmaceuticals today announced that Uli Hacksell and and I am confident we will build significant value for both patients and owners Cerecor Losses Impact New CEO Dr Mar 27, 2021 Dr. Uli Hacksell's total compensation package for 2016 was valued at $1.7 Cerecor reported a net income loss per share of 18 cents in the "We thank Rob for his service and wish him well in his future endeavors," said Dr Uli Hacksell, Chairman of the Board. About Cerecor Cerecor is a biopharmaceutical company focused on near term goal of becoming the leading U.S. pediatric pharmaceutical company while developing innovative therapies that make a difference in the lives of patients.